- Home
- EVAX vs RDHL Comparison
EVAX vs RDHL Comparison
Compare EVAX & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- RDHL
- Stock Information
- Founded
- EVAX 2008
- RDHL 2009
- Country
- EVAX Denmark
- RDHL Israel
- Employees
- EVAX N/A
- RDHL N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- RDHL Health Care
- Exchange
- EVAX Nasdaq
- RDHL Nasdaq
- Market Cap
- EVAX 17.8M
- RDHL 3.9M
- IPO Year
- EVAX 2021
- RDHL N/A
- Fundamental
- Price
- EVAX $2.90
- RDHL $1.50
- Analyst Decision
- EVAX Strong Buy
- RDHL
- Analyst Count
- EVAX 2
- RDHL 0
- Target Price
- EVAX $10.00
- RDHL N/A
- AVG Volume (30 Days)
- EVAX 89.0K
- RDHL 88.3K
- Earning Date
- EVAX 10-30-2025
- RDHL 09-05-2025
- Dividend Yield
- EVAX N/A
- RDHL N/A
- EPS Growth
- EVAX N/A
- RDHL N/A
- EPS
- EVAX N/A
- RDHL N/A
- Revenue
- EVAX $3,176,000.00
- RDHL $9,550,000.00
- Revenue This Year
- EVAX N/A
- RDHL $381.91
- Revenue Next Year
- EVAX N/A
- RDHL N/A
- P/E Ratio
- EVAX N/A
- RDHL N/A
- Revenue Growth
- EVAX 1042.45
- RDHL 157.62
- 52 Week Low
- EVAX $1.20
- RDHL $1.06
- 52 Week High
- EVAX $17.20
- RDHL $11.70
- Technical
- Relative Strength Index (RSI)
- EVAX 50.88
- RDHL 53.60
- Support Level
- EVAX $2.71
- RDHL $1.22
- Resistance Level
- EVAX $3.04
- RDHL $1.60
- Average True Range (ATR)
- EVAX 0.20
- RDHL 0.08
- MACD
- EVAX -0.01
- RDHL 0.04
- Stochastic Oscillator
- EVAX 55.97
- RDHL 73.68
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.